View all trials
Are you a member? Sign in above to view additional information
  • Study title
    Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics & Clinical Activity of the MEK Inhibitor Trametinib in children and adolescent subjects with Cancer or Plexiform Neurofibromas & Trametinib
  • Protocol ID
    GSK MEK
  • Disease
    Disease Type Disease Subtype
    Solid tumours
    Other Solid Tumour
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Children's Hospital at Westmead
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 1/2
  • Study type
    Treatment
  • Diagnosis stage
  • Study open date
    07/01/2015
  • Study close date
    N/A
  • Study chair
  • Sponsor
    GSK
Back to search results